Skip to main content

Table 10 Tissue silver content after 90-day oral administration of silver nanoparticles

From: Subchronic oral toxicity of silver nanoparticles

Silver (μg/g wet weight)
Dose/Sex Testes Liver Kidneys Brain Lungs Blood
0 mg/Kg       
Male 0.04 ± 0.02 0.02 ± 0.01 0.04 ± 0.02 0.02 ± 0.01 a 0.10 ± 0.08 0.001 ± 0.000
Female   0.01 ± 0.01 0.03 ± 0.01 0.01 ± 0.01 a 0.05 ± 0.02 0.002 ± 0.002
30 mg/Kg       
Male 6.56 ± 0.33** 4.20 ± 1.57** a 1.49 ± 0.37** b 0.47 ± 0.18** 1.94 ± 0.64** b 0.111 ± 0.016**
Female   8.56 ± 3.22** a 7.98 ± 0.91** b 0.38 ± 0.05** 4.97 ± 0.90 b 0.087 ± 0.017**
125 mg/Kg       
Male 11.84 ± 1.62** 10.19 ± 2.09** b 8.82 ± 2.13** b 0.69 ± 0.06** 10.97 ± 3.81** 0.191 ± 0.037** b
Female   29.13 ± 9.74** b 37.09 ± 17.44** b 0.77 ± 0.11** 17.64 ± 9.06** 0.122 ± 0.010** b
500 mg/Kg       
Male 23.75 ± 9.13** 68.65 ± 33.59** 99.19 ± 32.82** b 3.54 ± 1.44** 56.04 ± 51.14 0.419 ± 0.083**
Female   98.75 ± 31.65** 226.88 ± 55.64** b 3.70 ± 1.17** 45.83 ± 11.43** 0.303 ± 0.099**
  1. **Significant difference vs. control, p < 0.01. (ANOVA)
  2. a Significant difference vs. distinction of sex, p < 0.05. (T-test)
  3. b Significant difference vs. distinction of sex, p < 0.01. (T-test)